USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: Biomol Research Laboratoryt
City: Plymouth Meeting
State: PA
Zip+4: 19462
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $299,834.00 6

Award List:

THE GOAL OF THIS RESEARCH IS TO DEVELOP A HIGHLY SENSITIVE AND SPECIFIC RADIOIMMUNOASSAY FOR LEUKOTRIENE E4 AND LEUKOTRIENE E4-N-ACETATE, TWO IMPORTANT METABOLITES OF LEUKOTRIENE C4 AND D4.

Award Year / Program / Phase: 1986 / SBIR / Phase I
Agency: HHS
Principal Investigator: Robert e zipkin , PRINCIPAL INVESTIGATOR
Award Amount: $50,000.00
Abstract:
The goal of this research is to develop a highly sensitive and specific radioimmunoassay for leukotriene e4 and leukotriene e4-n-acetate, two important metabolites of leukotriene c4 and d4. these leukotrienes are potent bronco- and coronary artery vasoconstrictors, increase vascular permeability,… More

RADIO IMMUNOASSAY KITS FOR PLATELET ACTIVATING FACTOR

Award Year / Program / Phase: 1988 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $50,000.00
Abstract:
The goal of the proposed research is to develop a highly sensitive and specific radioimmunoassay for platelet activating factor (paf). paf is a lipid mediator produced by a variety of inflammatory cells such as neutrophils, platelets, macrophages, eosinophils, and vascular endothelial cells. paf… More

NOVEL THERAPEUTIC AGENT FOR MYOCARDIAL INFARCTION

Award Year / Program / Phase: 1990 / SBIR / Phase I
Agency: HHS
Principal Investigator: Robert E Zipkin
Award Amount: $50,000.00
Abstract:
The goal of this research is to develop a potent and specific pharmacologically useful antagonist to the leukotriene b4 (ltb4) receptor for use as a new therapeutic agent in myocardial infarction. ltb4 is a lipid mediator produced by a variety of inflammatory cells via the arachidonic acid… More

NOVEL ANTICANCER DRUGS BASED ON GLYCOLIPID DEPLETION

Award Year / Program / Phase: 1992 / SBIR / Phase I
Agency: HHS
Principal Investigator: Robert E Zipkin
Award Amount: $50,000.00
Abstract:
The goal of the research is to develop a potent pharmacologically useful inhibitor of glycosphingolipid (gsl) biosynthesis. gsls play important roles in (1) cancer cell metastasis, proliferation, and resistance against the host's immunosurveillance system, (2) the binding and activation of… More

Farnesyltransferase Inhibitors As Anticancer Agents

Award Year / Program / Phase: 1993 / SBIR / Phase I
Agency: HHS
Principal Investigator: Robert E. Zipkin
Award Amount: $50,000.00
Abstract:
The goal of the research is to develop a potent, pharmacologically useful inhibitor of farnesyltransferase for use as a new therapeutic agent for cancer. The Ras family of oncogenes and proto-oncogenes encode guanine nucleotide binding proteins that participate in the control of eukaryotic cell… More

Tyrosine Phosphatase Inhibitors As New Immunomodulators

Award Year / Program / Phase: 1993 / SBIR / Phase I
Agency: HHS
Principal Investigator: Robert E. Zipkin
Award Amount: $49,834.00
Abstract:
The goal of the research is to develop a potent pharmacologically useful inhibitor of the CD45 protein tyrosine phosphatase. CD45 is a transmembrane protein having a highly glycosylated extracellular region and a cytosolic domain which possesses tyrosine phosphatase activity. CD45 plays a critical… More